BPO-27 racemate

• CAT Number: I013692
• CAS Number: 1314873-02-3
• Molecular Formula: C₂₆H₁₈BrN₃O₆
• Molecular Weight: 548.34
• Purity: ≥95%
• Target: Autophagy
• Solubility: DMSO: 6 mg/mL
• IUPAC Name: 9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid
• InChI: InChI=1S/C26H18BrN3O6/c1-28-21-19(24(31)29(2)26(28)34)20(13-6-4-3-5-7-13)30-15-12-14(25(32)33)8-9-16(15)36-23(22(21)30)17-10-11-18(27)35-17/h3-12,23H,1-2H3,(H,32,33)
• InChIKey: GNHIGSRGYXEQEP-UHFFFAOYSA-N
• SMILES: CN1C2=C3C(OC4=C(N3C(=C2C(=O)N(C1=O)C)C5=CC=CC=C5)C=C(C=C4)C(=O)O)C6=CC=C(O6)Br

BPO-27 racemate (Cat.No:I013692) is a potent inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, with an IC₅₀ of 8 nM. It comprises equal parts of two enantiomers: the R-enantiomer, which exhibits significant inhibitory activity (IC₅₀ of 4 nM), and the S-enantiomer, which is inactive. BPO-27 racemate is utilized in research focused on CFTR-related functions and diseases, including cystic fibrosis and polycystic kidney disease. Its metabolic stability and efficacy make it a valuable tool for studying CFTR inhibition and associated therapeutic interventions.